Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Treasury Shares (2021 - 2026)

Lucid Diagnostics filings provide 5 years of Treasury Shares readings, the most recent being $6.6 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 68.94% to $6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 68.94% increase, with the full-year FY2025 number at $6.6 million, up 68.94% from a year prior.
  • Treasury Shares hit $6.6 million in Q4 2025 for Lucid Diagnostics, roughly flat from $6.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $6.6 million in Q1 2025 to a low of $1.8 million in Q3 2023.
  • Median Treasury Shares over the past 5 years was $2.3 million (2024), compared with a mean of $3.5 million.
  • Biggest five-year swings in Treasury Shares: fell 17.19% in 2023 and later surged 186.59% in 2025.
  • Lucid Diagnostics' Treasury Shares stood at $1.9 million in 2021, then increased by 7.76% to $2.1 million in 2022, then increased by 11.76% to $2.3 million in 2023, then skyrocketed by 66.74% to $3.9 million in 2024, then surged by 68.94% to $6.6 million in 2025.
  • The last three reported values for Treasury Shares were $6.6 million (Q4 2025), $6.6 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.